Clinical Trials on Hepatitis C Virus

Total 24861 results

AbbVie

Completed

Observational, Multi-Center Study of the Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation (HCV RWE)

Chronic Hepatitis C | Genotype 1
Debiopharm International SA

Completed

Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option

Hepatitis C | Liver Disease

United States, France
Hoffmann-La Roche

Completed

A Study on Safety, Tolerability and Pharmacokinetics of RO5303253 in Healthy Volunteers and Patients With Chronic Hepatitis C Genotype 1

Hepatitis C, Chronic, Healthy Volunteer

New Zealand
Hoffmann-La Roche

Completed

A Study of RO5428029 in Healthy Volunteers and Patients With Chronic Hepatitis C

Hepatitis C, Chronic, Healthy Volunteer

Poland, France, Netherlands
Merck Sharp & Dohme LLC

Completed

MRKAd5 HIV-1 Gag Vaccine (V520) in Subjects With Chronic Hepatitis C (V520-022) (COMPLETED)

Hepatitis C
Johann Wolfgang Goethe University Hospital

Completed

Acoustic Radiation Force Impulse-Imaging in Comparison to Transient Elastography for Liver Fibrosis Staging in HCV

Chronic Hepatitis C

Netherlands, Germany, France
National Taiwan University Hospital

Completed

Prediction of Significant Hepatic Fibrosis in HCV Carriers With PNALT by SAPI- A Validation Study

Chronic Hepatitis C | Hepatic Fibrosis

Taiwan
University of Texas at Austin

Active, not recruiting

Implementing HCV Treatment for High-risk Populations in Austin, Texas

Hepatitis C Virus Infection

United States
AbbVie

Approved for marketing

Expanded Access to Glecaprevir/ Pibrentasvir

Hepatitis C Virus Infection

Slovenia
Gilead Sciences

Completed

Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study

Hepatitis C Virus Infection

Germany, United States, Australia, United Kingdom, Canada, France, New Zealand
Gilead Sciences

Completed

Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis (VALOR-HCV)

Hepatitis C Virus Infection

United States
Bristol-Myers Squibb

Completed

Absolute Bioavailability of BMS-791325

Hepatitis C Virus Infection

United Kingdom
AbbVie (prior sponsor, Abbott)

Completed

A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies

Hepatitis C Virus Infection

United States
Hanyang University
Roche Pharma AG

Completed

Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients (Addwin)

Chronic Hepatitis C

Korea, Republic of
Bristol-Myers Squibb

Terminated

Study of Daclatasvir-based Therapy in Chinese Participants With Chronic Hepatitis C (CHC)

Chronic Hepatitis C

China
Novartis

Completed

Albinterferon Alfa 2b Single Dose in Japanese Chronic Hepatitis C Patients

Chronic Hepatitis C

Japan
OPKO Health, Inc.

Completed

Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and Ribavirin

Hepatitis, Viral, Human | Chronic Hepatitis C

Canada
Alios Biopharma Inc.

Completed

First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1

Chronic Hepatitis C

France, Moldova, Republic of, Georgia
AbbVie

Completed

The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in France (OPALE)

Chronic Hepatitis C

France
AbbVie

Completed

The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland (REACH)

Chronic Hepatitis C
AbbVie
Cato Research; IST GmbH, Germany

Completed

Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada (AMBER)

Chronic Hepatitis C
Third Affiliated Hospital, Sun Yat-Sen University

Unknown

Real-world Effectiveness and Safety of Treatment With DAAs in Patients With CHC(Chronic Hepatitis C)

Chronic Hepatitis C
AbbVie
IST GmbH, Germany

Completed

Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Romania

Chronic Hepatitis C
Bristol-Myers Squibb

Completed

Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C

Chronic Hepatitis C

Japan
Debiopharm International SA

Terminated

Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1

Hepatitis C

United States
Novartis
Human Genome Sciences Inc.

Completed

Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients

Chronic Hepatitis C

Taiwan, Germany, Greece, Italy, Spain, United Kingdom, France, Canada, Australia, India, Poland, Thailand
Hoffmann-La Roche

Completed

Observational Study Evaluating the Quality of Pegylated Interferon Alfa-2a and Ribavirin Treatment for Chronic Hepatitis C in Cooperation With the BNG (Association of German Resident Gastroenterologists)

Chronic Hepatitis C

Germany
Pharco Pharmaceuticals

Unknown

A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4

Chronic Hepatitis C

Egypt
Center For Hepatitis C, Atlanta, GA

Completed

The SIM-SOF Trial for Hepatitis C

Chronic Hepatitis C

United States
Bristol-Myers Squibb

No longer available

A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C

Chronic Hepatitis C

United States
Merck Sharp & Dohme LLC

Completed

Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)

Chronic Hepatitis C
Beijing 302 Hospital

Unknown

Pharmacogenomics Study on IL28B Genetic Variants in Chinese Children With Hepatitis C Virus Infection

Chronic Hepatitis C

China
Haukeland University Hospital
Hoffmann-La Roche; Bergen Prison, Norwegian Correctional Service

Terminated

Hepatitis C Treatment of Inmates (PEGPRI)

Chronic Hepatitis C

Norway
Beijing Kawin Technology Share-Holding Co., Ltd.

Completed

A Phase Ⅱ Dose-escalating Study of PEG-IFN-SA and Ribavirin in IFN Naive Patients With Chronic Hepatitis C

Chronic Hepatitis C

China
CureTech Ltd
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection

Chronic Hepatitis C

Israel
Tibotec BVBA

Completed

An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants

Chronic Hepatitis C

France, Spain, Belgium, Germany, Austria, Netherlands
Santaris Pharma A/S

Unknown

Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C

Hepatitis C

Puerto Rico
Inje University

Completed

Pharmacogenomic Research in Korean Patients With Hepatitis C

Chronic Hepatitis C

Korea, Republic of
Xiamen Amoytop Biotech Co., Ltd.
Peking University People's Hospital

Completed

Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C (PEGIFN)

Chronic Hepatitis C

China
Hospital Universitario Ramon y Cajal

Terminated

Efficacy of Long-term Ribavirin in Non-responders With Chronic Hepatitis C and Advanced Fibrosis (RIBACIR)

Chronic Hepatitis C

Spain
Göteborg University
Hoffmann-La Roche

Terminated

Combination Therapy With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Who Previously Have Relapsed After Therapy With Pegylated Interferon and Ribavirin (RelapC)

Chronic Hepatitis C

Sweden
SciClone Pharmaceuticals

Completed

Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed

Chronic Hepatitis C

United States
Catalysis SL

Completed

Antioxidant and Immunomodulator Properties of Viusid in Patients With Chronic Hepatitis C

Chronic Hepatitis C

Cuba
Pusan National University Yangsan Hospital
Pusan National University Hospital; Inje University; Severance Hospital; Soon Chun... and other collaborators

Unknown

PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR)

Chronic Hepatitis C

Korea, Republic of
Federico II University

Withdrawn

24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C

Chronic Hepatitis C

Italy
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C

Chronic Hepatitis C

Japan
Prof. Facchinetti Fabio
Merck Sharp & Dohme LLC

Completed

Menopause is a Critical Factor in Determining Failure of Antiviral Therapy in Women With Chronic Hepatitis C (MEN_EPID)

Chronic Hepatitis C

Italy
Merck Sharp & Dohme LLC

Completed

Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C

Chronic Hepatitis C

United States, Puerto Rico
Bader, Ted, M.D.

Completed

Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy

Chronic Hepatitis C

United States
Pevion Biotech Ltd

Completed

Phase I Hepatitis C Vaccine Trial of Virosome-formulated Peptides

Chronic Hepatitis C

Switzerland

3

Subscribe